FindTrial
Sign In

IM96 CAR-T Cells

BIOLOGICAL3 trials

Sponsors

Beijing Immunochina Medical Science & Technology Co., Ltd.

Conditions

Adenocarcinoma of Esophagogastric JunctionAdenocarcinoma of GastricAdvanced Solid TumorsColorectal (Colon or Rectal) CancerColorectal Cancer (CRC)Digestive System NeoplasmsPancreatic Cancer Resectable

Early Phase 1

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
NCT05287165
Beijing Immunochina Medical Science & Technology Co., Ltd.Advanced Solid Tumors, Colorectal (Colon or Rectal) Cancer, Digestive System Neoplasms +1
Start: 2022-03-10End: 2024-06-30Target: 19Updated: 2022-03-18

Phase 1

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
RecruitingNCT06718738
Beijing Immunochina Medical Science & Technology Co., Ltd.Colorectal Cancer (CRC)
Start: 2024-12-15End: 2026-08-15Target: 9Updated: 2024-12-05
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction
Not yet recruitingNCT07406984
Beijing Immunochina Medical Science & Technology Co., Ltd.Adenocarcinoma of Esophagogastric Junction, Adenocarcinoma of Gastric
Start: 2026-03-05End: 2027-12-31Target: 18Updated: 2026-02-13

Related Papers

Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer.
Journal of Clinical Oncology2024-06-019 citations